Brought to you by 
Idun Pharmaceuticals completes private placement
04 Mar 2005
Executive Summary
Idun Pharmaceuticals (develops drug candidates to control apoptosis) completed a $22.8mm private placement of preferred stock led by Ventana Capital Management. New investors GeneChem Management, Hambrecht and Quist Capital Management (HQCM), RBC Capital Partners, BioVeda Capital, and Sorrento Associates were joined by returning investors Venrock Associates and Arch Venture Partners.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Idun Pharmaceuticals completes private placement
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice